|
KMID : 0882419930440040464
|
|
Korean Journal of Medicine
1993 Volume.44 No. 4 p.464 ~ p.473
|
|
|
Comparison of the Long-term Survival between Standard-and High-risk Leukemia Patients received Allogeneic Bone Marrow Transplantation
|
|
최정현
김희제/이종욱/진종률/한치화/민우성/박종원/김춘추/김동집
|
|
|
Abstract
|
|
|
ackground : To asses the relationship between disease status at transplant the long-term
disease-free survival (DFS) in patients with acute and chronic leukemia, we compared the
DFS of standard risk group and that of high risk group after allogeneic bone marrow
transplantation (BMT).
Methods ; Between March 1983 and December 1990, 58 patients with acute or chronic
leukemia who had been underwent the allogeneic BMT at St. Mary's Hospital of Catholic
University Medical College were assigned to a retrospective study comparing DFS of standard
risk group with that of high risk group. We defined standard risk group (n=32) as the first
complete remission (CR) in AML and ALL of adult type, the second CR of ALL of childhood
type and the chronic phase of CML. Advanced disease state beyond the standard risk group
was considered as high risk group (n=26).
Results ;
1) In AML, after median follow-up of 26 months (3∼55 months) long-term DFS of
standard risk group was higher (62%) than that of high risk group (10%)(p<0.01).
2) In ALL of adult type, after median follow-up of 36 months (3∼93 months) long-term
DFS between standard risk and high risk group was 67% and 60%, respectively (p=0.2).
3) In CML, after median follow-up of 27 months (3∼52 months) long-terms DFS of
standard risk group was 89% and that of high risk group was 36% (p<0.01).
4) Compared to the 72% (23/32) survival rate of standard risk leukemia, that of high risk
leukemia was 31% (8/26)(p<0.01).
5) Relapse of leukemia ws the most frequently encountered complication (29%) and the
most common cause of death (54%) after allogeneic BMT.
Conclusion : Our results show that the outcome of standard risk group appears to be
superior to that of high risk group in patients with acute and chronic leukemia. Therefore
we would like to recommend to perform BMT in the early stage of disease for the treatment
of acute and chronic leukemia to improve the long-term DFS.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|